Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …

Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Identifying locoregional gastric cancer patients who are at high risk for relapse after
resection could facilitate early intervention. By detecting molecular residual disease (MRD) …

Colon cancer continues to be one of the leading causes of mortality and morbidity
throughout the world despite the availability of reliable screening tools and effective …

Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …

Advances in DNA sequencing methods have significantly expanded the potential clinical
applications of analyzing circulating tumor DNA (ctDNA). This genetic information can …

Simple Summary Currently, the treatment for localized colon cancer consists of surgery and,
if the presence of residual cancer cells is suspected, chemotherapy following the surgery …

Advances in diagnosis and treatment have resulted in a high rate of survival for many
patients with early-stage cancers. However, identifying who is at ongoing risk of relapse …